Luteolin

Research use only, not for human use.

Luteolin is a falconoid compound, which exhibits anticancer properties.

Luteolin is a falconoid compound, which exhibits anticancer properties.(In Vitro):Luteolin (0-160 μM; 24 hours; NCI-H460 cells) treatment inhibits the viability of NCI-H460 cells in a concentration-dependent manner.Luteolin (20-80 μM; 24 hours; NCI-H460 cells) treatment causes an accumulation of cells in the S phase.Luteolin (320-580 μM; 48 hours; NCI-H460 cells) treatment induces apoptosis.Luteolin (20-80 μM; 24 hours; NCI-H460 cells) treatment increases the protein expression levels of apoptotic regulatory proteins, including the Bax/Bcl-2 ratio, in a concentration-dependent manner, however, only 80 μM Luteolin inhibits the expression of Bad. Luteolin also decreases the expression of Sirt1 in the NCI-H460 cell line in a concentration-dependent manner.(In Vivo):Luteolin (10-100 mg/kg; oral gavage; daily; for 12 weeks; adult male Wistar rats) has an antioxidant effect and can also protect against non-alcoholic steatohepatitis through targeting the pro-inflammatory IL-1 and Il-18 pathways in rats with a high carbohydrate/high fat diet.

——

——

BRN 0292084 | Digitoflavone | Flacitran | Luteoline | Luteolol | Salifazide | Luteolin

Angiogenesis

PDE

PDE1| PDE2| PDE3| PDE4| PDE5

Other Indications

——

491-70-3

286.24

C15H10O6

>98% (HPLC)

Ethanol: 3 mg/mL warmed (10.48 mM); DMSO: 57 mg/mL (199.13 mM)

O=C1C=C(C2=CC=C(O)C(O)=C2)OC3=CC(O)=CC(O)=C13

2-(3,4-Dihydroxyphenyl)-5,7-dihydroxy-4-benzopyrone

(-20℃)

With Ice Pack

≥ 2 years